APOBR (apolipoprotein B receptor) is a macrophage receptor that mediates the high-affinity uptake and internalization of triglyceride-rich lipoproteins, including chylomicrons and apolipoprotein B48-containing particles 1. The receptor binds apolipoprotein B48 of dietary triglycerides and hypertriglyceridemic VLDL, potentially facilitating foam cell formation and providing essential lipids to reticuloendothelial cells. APOBR has emerged as a multisystem disease candidate through large-scale genetic studies. Genome-wide association analyses identified APOBR variants associated with extreme obesity in the chr16.2 locus, with two polymorphisms (rs180743 and rs3833080) showing nominal association 1. In type 1 diabetes, APOBR colocalized with disease GWAS signals in newborns, with Mendelian randomization evidence implicating APOBR in disease aetiology 2. APOBR has also been genetically associated with preeclampsia 3, hypothyroidism (via the c.C1883G mutation affecting the Na+/Ca2+ exchanger superfamily domain) 4, allergic diseases 5, obstructive sleep-disordered breathing (with downregulation in EBV+ and CPAP-dependent cases) 6, bladder cancer risk 7, and cannabis exposure-associated DNA methylation changes 8. These diverse associations suggest APOBR participates in lipid metabolism pathways with broader physiological implications beyond lipoprotein uptake.